Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial.

NCT01005199 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT01005199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01005199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
March 31, 2016
Enrollment
106 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer